文献速递胸部肿瘤

2021年美国癌症统计报告

Cancer Statistics, 2021.
PubMed 文献 · CA Cancer J Clin · 2021-01-12

美国癌症协会每年估算美国新发癌症病例和死亡人数,并汇编基于人群的癌症发生最新数据。2021年预计美国新发癌症病例1,898,160例,癌症死亡608,570例。

要点

  • 2021年美国预计新发癌症1,898,160例,死亡608,570例。
  • 肺癌死亡率年降幅加速,男性从3.1%增至5.5%,女性从1.8%增至4.4%。

核心结论

  • 癌症死亡率自1991年峰值至2018年持续下降,累计降幅31%,归因于吸烟减少及早诊治疗进步。
  • 肺癌死亡率下降加速,占2014至2018年总死亡率下降的近一半,与NSCLC生存率快速提升同步。

研究设计与样本

  • 基于美国人群的癌症统计报告,发病率数据截至2017年来自SEER、NPCR和NAACCR,死亡率数据截至2018年来自NCHS。

主要发现

  • 2021年美国预计新发癌症病例1,898,160例,癌症死亡608,570例。
  • 肺癌死亡率年降幅在男性从2009-2013年的3.1%增至2014-2018年的5.5%,女性从1.8%增至4.4%,总体从2.4%增至5%。
  • NSCLC 2年相对生存率从2009-2010年诊断的34%升至2015-2016年诊断的42%,各诊断分期绝对增加5%至6%;小细胞肺癌生存率维持在14%至15%。
  • 前列腺癌死亡率长期下降停滞,乳腺癌和结直肠癌死亡率下降放缓。

临床怎么用

  • 肺癌死亡率加速下降与NSCLC生存改善相关,提示早诊和治疗进步对降低癌症负担的作用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Each year, the American Cancer Society estimates the numbers of new cancer cases and deaths in the United States and compiles the most recent data on population-based cancer occurrence. Incidence data (through 2017) were collected by the Surveillance, Epidemiology, and End Results Program; the National Program of Cancer Registries; and the North American Association of Central Cancer Registries. Mortality data (through 2018) were collected by the National Center for Health Statistics. In 2021, 1,898,160 new cancer cases and 608,570 cancer deaths are projected to occur in the United States. After increasing for most of the 20th century, the cancer death rate has fallen continuously from its peak in 1991 through 2018, for a total decline of 31%, because of reductions in smoking and improvements in early detection and treatment. This translates to 3.2 million fewer cancer deaths than would have occurred if peak rates had persisted. Long-term declines in mortality for the 4 leading cancers have halted for prostate cancer and slowed for breast and colorectal cancers, but accelerated for lung cancer, which accounted for almost one-half of the total mortality decline from 2014 to 2018. The pace of the annual decline in lung cancer mortality doubled from 3.1% during 2009 through 2013 to 5.5% during 2014 through 2018 in men, from 1.8% to 4.4% in women, and from 2.4% to 5% overall. This trend coincides with steady declines in incidence (2.2%-2.3%) but rapid gains in survival specifically for nonsmall cell lung cancer (NSCLC). For example, NSCLC 2-year relative survival increased from 34% for persons diagnosed during 2009 through 2010 to 42% during 2015 through 2016, including absolute increases of 5% to 6% for every stage of diagnosis; survival for small cell lung cancer remained at 14% to 15%. Improved treatment accelerated progress against lung cancer and drove a record drop in overall cancer mortality, despite slowing momentum for other common cancers.

来源:CA Cancer J Clin,查看原文。版权归原作者所有。

引用

  1. Siegel RL, Miller KD, Fuchs HE, et al. Cancer Statistics, 2021. CA Cancer J Clin. 2021. PMID: 33433946. doi:10.3322/caac.21654

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。